Provectus Biotech, Inc.
Overview
Provectus’ biotechnology division is based on patented, cost-effective methods used to improve the yield or performance of recombinant DNA products (including enzymes, antigens, drugs or other proteins) and vaccines. This is achieved through a one-time genetic modification of the cells that produce these products.

In addition, Provectus holds an innovative “virus hunter” method used to identify dangerous new viruses. This technology may play a crucial role in discovering the underlying cause of certain cancers and other serious diseases, and ultimately in producing preventative vaccines. For instance, the recent demonstration that vaccination against human papillomavirus (HPV) may prevent cervical cancer illustrates that many cancers may be caused by viruses. Provectus’ technology may be used by pharmaceutical companies to discover the cause and develop preventative vaccines against cancers of the breast, prostate and other parts of the body.

Provectus holds four biotechnology patents and intends to license this portfolio to major partners in the pharmaceutical industry. To date, Schering-Plough has purchased a non-exclusive license from Provectus to enhance production and performance of veterinary vaccines.

Key Attributes of Provectus’ Biotechnology:

• Increase yield of vaccines
• Increase vaccine immunogenicity (ability to stimulate an immune response)
• Increase yield and performance of products produced by genetic engineerin
• Potentially isolate as-yet-undiscovered viruses
• Potentially create new diagnostic tests for cancers
• Potentially develop vaccines against virus-induced cancers